Literature DB >> 17285139

Antisense oligonucleotide-induced exon skipping across the human dystrophin gene transcript.

Steve D Wilton1, Abbie M Fall, Penny L Harding, Graham McClorey, Catherine Coleman, Susan Fletcher.   

Abstract

Protein-truncating mutations in the dystrophin gene lead to the most common childhood form of muscle wasting, Duchenne muscular dystrophy. Becker muscular dystrophy, a condition that typically arises from dystrophin gene lesions that do not disrupt the reading frame, clearly indicates that substantial domains of the dystrophin protein are not essential. Potential therapeutic intervention exists during pre-mRNA splicing, whereby selected exons are excised to either remove nonsense mutations or restore the reading frame around frame-shifting mutations from the mature mRNA. Appropriately designed antisense oligonucleotides (AOs), directed at amenable splicing motifs across the dystrophin gene transcript, block exon recognition and/or spliceosome assembly so that targeted exons are removed from the mature mRNA. We describe a panel of AOs designed to induce skipping of every exon within the human dystrophin gene transcript, with the exception of the first and last exons. Every exon targeted in vitro could be removed from the dystrophin mRNA, although some exons are more efficiently excluded than others. No single motif has emerged as a universal AO annealing site for redirection of dystrophin pre-mRNA processing, although the general trend is that the most efficient compounds are directed at motifs in the first half of the target exon.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17285139     DOI: 10.1038/sj.mt.6300095

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  66 in total

1.  Premature termination codons in the DMD gene cause reduced local mRNA synthesis.

Authors:  Raquel García-Rodríguez; Monika Hiller; Laura Jiménez-Gracia; Zarah van der Pal; Judit Balog; Kevin Adamzek; Annemieke Aartsma-Rus; Pietro Spitali
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-02       Impact factor: 11.205

2.  Personalized exon skipping strategies to address clustered non-deletion dystrophin mutations.

Authors:  Sarah Forrest; Penny L Meloni; Francesco Muntoni; Jihee Kim; Sue Fletcher; Steve D Wilton
Journal:  Neuromuscul Disord       Date:  2010-12       Impact factor: 4.296

3.  Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.

Authors:  Yusuke Echigoya; Kenji Rowel Q Lim; Nhu Trieu; Bo Bao; Bailey Miskew Nichols; Maria Candida Vila; James S Novak; Yuko Hara; Joshua Lee; Aleksander Touznik; Kamel Mamchaoui; Yoshitsugu Aoki; Shin'ichi Takeda; Kanneboyina Nagaraju; Vincent Mouly; Rika Maruyama; William Duddy; Toshifumi Yokota
Journal:  Mol Ther       Date:  2017-07-28       Impact factor: 11.454

4.  Rational design of antisense oligomers to induce dystrophin exon skipping.

Authors:  Chalermchai Mitrpant; Abbie M Adams; Penny L Meloni; Francesco Muntoni; Sue Fletcher; Steve D Wilton
Journal:  Mol Ther       Date:  2009-03-17       Impact factor: 11.454

5.  Guidelines for antisense oligonucleotide design and insight into splice-modulating mechanisms.

Authors:  Annemieke Aartsma-Rus; Laura van Vliet; Marscha Hirschi; Anneke A M Janson; Hans Heemskerk; Christa L de Winter; Sjef de Kimpe; Judith C T van Deutekom; Peter A C 't Hoen; Gert-Jan B van Ommen
Journal:  Mol Ther       Date:  2008-09-23       Impact factor: 11.454

6.  Design of phosphorodiamidate morpholino oligomers (PMOs) for the induction of exon skipping of the human DMD gene.

Authors:  Linda J Popplewell; Capucine Trollet; George Dickson; Ian R Graham
Journal:  Mol Ther       Date:  2009-01-13       Impact factor: 11.454

7.  Guanine analogues enhance antisense oligonucleotide-induced exon skipping in dystrophin gene in vitro and in vivo.

Authors:  Yihong Hu; Bo Wu; Allen Zillmer; Peijuan Lu; Ehsan Benrashid; Mingxing Wang; Timothy Doran; Mona Shaban; Xiaohua Wu; Qi Long Lu
Journal:  Mol Ther       Date:  2010-01-19       Impact factor: 11.454

8.  Therapeutic exon skipping for dysferlinopathies?

Authors:  Annemieke Aartsma-Rus; Kavita H K Singh; Ivo F A C Fokkema; Ieke B Ginjaar; Gert-Jan van Ommen; Johan T den Dunnen; Silvère M van der Maarel
Journal:  Eur J Hum Genet       Date:  2010-02-10       Impact factor: 4.246

9.  Antisense PMO found in dystrophic dog model was effective in cells from exon 7-deleted DMD patient.

Authors:  Takashi Saito; Akinori Nakamura; Yoshitsugu Aoki; Toshifumi Yokota; Takashi Okada; Makiko Osawa; Shin'ichi Takeda
Journal:  PLoS One       Date:  2010-08-18       Impact factor: 3.240

10.  Enhanced exon-skipping induced by U7 snRNA carrying a splicing silencer sequence: Promising tool for DMD therapy.

Authors:  Aurélie Goyenvalle; Arran Babbs; Gert-Jan B van Ommen; Luis Garcia; Kay E Davies
Journal:  Mol Ther       Date:  2009-05-19       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.